Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 21,022 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Adherence, Patient, TB, HIV/AIDS, Care Coordination
Interventions: CHW mHealth patient intervention for trigger escalation; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions: Registry, PK microsampling of blood; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: Not listed
Lead sponsor: Ekips Technologies; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Norman, Oklahoma

Conditions: Smoldering Multiple Myeloma
Interventions: Selinexor; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 58
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more

Conditions: Dermatitis, Atopic
Interventions: Bathing Additive; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Lymphocytic Leukemia
Interventions: SPC2996; Drug
Lead sponsor: Santaris Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infections
Interventions: Popular Opinion Leader; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Multiple Myeloma, Plasma Cell Neoplasm, Malignant Plasma Cell Neoplasm
Interventions: Radiation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: CAB-RPV LA, Standard treatment within an HIV clinic; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Refractory Solid Tumors, Lymphomas
Interventions: Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Systemic Lupus Erythematosus
Interventions: atorvastatin; Drug
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Rheumatoid Arthritis
Interventions: PF-06438179, Infliximab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 43
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
Interventions: clonoSEQ Assay; Diagnostic Test
Lead sponsor: Adaptive Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Stanford, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 10 more

Conditions: Attention Deficit Hyperactivity Disorder, Asthma, Autism Spectrum Disorder, Depression, Epilepsy
Interventions: TriVox for clinical care; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 946 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Teclistamab Monotherapy, Teclistamab; Drug
Lead sponsor: Multiple Myeloma Research Consortium; Network
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 13
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Asthma
Interventions: coconut oil; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Xerostomia, Sjogren's Syndrome
Interventions: P-552, Placebo; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: HXe MRI guided treatment sequence for BT, Standard treatment sequence for BT (control); Drug · Other
Lead sponsor: Xemed LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections, Hepatitis C
Interventions: Silymarin, Placebo; Drug
Lead sponsor: Henry Sacks; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Bronchoscopy; Procedure
Lead sponsor: University of Virginia; Other
Eligibility: Up to 17 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Solid Tumor Cancer, Lymphoma
Interventions: SB-485232; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions: Tositumomab and Iodine I 131 Tositumomab; Combination Product
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: IgG4 Related Disease
Interventions: ACE1831, Lymphodepleting chemotherapy; Drug
Lead sponsor: Acepodia Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Search by objective public record fields.

Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

Development of a Breath Analyzer for Asthma Screening

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Bathing Additives in Pediatric Atopic Dermatitis

SPC2996 in Chronic Lymphocytic Leukaemia

ADAPT-POL: Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Improving Treatment and Retention Adherence in Nontraditional Settings

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

The clonoSEQ® Watch Registry

Using an Online Patient Monitoring System to Improve Care for Children With Chronic Conditions

MMRC Horizon One: RRMM (MMRC-099)

Fatty Acids in Airway Smooth Muscle of Asthmatics

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI

A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease